Needham & Company Reiterates a 'Buy' on Vivus (VVUS); Contrave FDA Advisory Committee Vote a Positive for Obesity Space, Qnexa, and Vivus
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Vivus (NASDAQ: VVUS), PT $15.
Needham analyst says, "An FDA Advisory Committee surprisingly ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "An FDA Advisory Committee surprisingly ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
